Zeliha Chaffin
(The World)
Published on September 29, 2024 at 07:42. / Modified on September 29, 2024 at 07:44.
Are we witnessing a turning point in the fight against obesity? After decades of failures in the development of effective treatments, the arrival of a new generation of drugs, which displays particularly promising clinical results (15% to 20% weight loss on average), is sparking a great enthusiasm among patients in recent years. To the point that their manufacturers, overwhelmed by orders, are struggling to meet demand, despite factories operating at full capacity.
With more than a billion people worldwide affected by obesity, including 890 million adults, there is no shortage of potential customers for these treatments. Especially since these numbers continue to grow. In the space of thirty years, the obesity rate has more than doubled among adults and quadrupled among children and adolescents. A boon for the Danish Novo Nordisk and the American Lilly, the pharmaceutical laboratories behind Wegovy and Zepbound, these new coveted anti-obesity drugs. Manufacturers have not had to make much effort to popularize their products. On social networks, euphoric anonymous people, with viral photos before and after treatment, took it upon themselves to promote it. Just like celebrities, like Elon Musk or Oprah Winfrey, who sing their praises.
Want to read all of our articles?
For CHF 29.- per month, enjoy unlimited access to our articles, without obligation!
I subscribe
Good reasons to subscribe to Le Temps:
- Unlimited access to all content available on the website.
- Unlimited access to all content available on the mobile application
- Sharing plan of 5 articles per month
- Consultation of the digital version of the newspaper from 10 p.m. the day before
- Access to supplements and T, the Temps magazine, in e-paper format
- Access to a set of exclusive benefits reserved for subscribers
Already a subscriber?
Log in
